Baxter International consensus picture builds, shares trade below recent highs
25.06.2026 - 17:27:25 | ad-hoc-news.de
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-25, 17:26.
Baxter International Inc. (US0673431090) sits on the NYSE with a mid-cap footprint in the US medical technology sector. Analyst statements around the stock sketch a cautious picture, as recent commentary highlights valuation constraints and competitive pressure in healthcare equipment and supplies.
What recent research notes show
MarketBeat data summarizes several analyst views on Baxter International, including rating changes and price-target adjustments. Zacks Research most recently moved its stance on the Baxter shares from a "strong sell" rating to "hold", signaling reduced downside conviction rather than a clear bullish turn.
Evercore ISI adjusted its target price on Baxter International shares, cutting the level from 23 dollars to 22 dollars while still labeling the stock "outperform" in its framework. This combination of a supportive rating with a lower target underlines how some analysts remain constructive on the business but see only muted upside on the current earnings and balance-sheet profile.
How the earnings backdrop looks
In its last reported quarter, Baxter International posted earnings per share of 0.36 dollars, beating the consensus expectation of 0.31 dollars per share by 0.05 dollars. Revenue trends and margin datapoints in that period fed into analyst valuation models, informing the more reserved target ranges visible in current broker commentary.
Price-performance data compiled by MarketBeat for Baxter International shows shares opening around 21.08 dollars in the latest snapshot, implying a market capitalization near 10.89 billion dollars for the medical instruments supplier. On those figures Baxter trades at a negative price-earnings ratio of roughly -9.90, reflecting the impact of special items and restructuring on reported net income.
All news and data on the Baxter International shares
Further company releases, price data and analyst updates on Baxter International can be found in the dedicated topic section and on the Investor Relations site.
The product behind the stock
Baxter International generates most of its revenue from hospital and clinical products such as infusion pumps, intravenous (IV) solutions and dialysis equipment used in renal therapy. The group also offers critical care devices and consumables that support anesthesiology, oncology and intensive care workflows in healthcare systems worldwide.
Where the stock trades today
The Baxter International shares (US0673431090) trade on the NYSE, with the latest price indication around 21.08 dollars on Thursday, based on MarketBeat price-performance data. That level places the stock below recent highs, reflecting the cautious analyst stance and valuation metrics currently attached to the name.
Key data on the Baxter International shares
- Company: Baxter International Inc.
- ISIN: US0673431090
- WKN: 856840
- Ticker: BAX
- Trading venue: NYSE
- Price (as of 2026-06-25, 17:26): 21.08 USD
- Market cap: 10.89 billion USD (as of 2026-06-25)
- Sector / industry: Health Care Equipment & Supplies
- Index membership: S&P 500
- Next earnings date: not officially scheduled
Disclaimer: This article is for informational purposes only and does not constitute investment advice, a recommendation or an offer to buy or sell securities.
